** Shares in Grifols GRLS.MC rise 6% after the Spanish pharmaceutical firm posted better-than-expected Q4 results with "show-stealing" FCF
** "Free cash flow steals the show," Berenberg says, referring to end-Q4 FCF of 335 million euros, which substantially beats its forecasts of 114 million euros
** J.P. Morgan also notes the key positive was FCF
** However, the brokerage says it would be prudent to wait for forward-looking outlook before giving full credit for the FCF improvement
** Grifols is set to reveal its 2025 and mid-term outlook later on Thursday
** The company also reports Q4 revenues of 1.98 billion euros ($2.07 billion), 4% above Visible Alpha consensus cited by Berenberg, and Q4 EBITDA of 526 million, slightly below the consensus
** Shares are on track for best day since mid-December, if gains hold, and second top performer on Madrid's IBEX 35 index .IBEX
($1 = 0.9545 euros)
(Reporting by Javi West Larrañaga)
((javier.west@thomsonreuters.com; +48 58 769 65 76))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.